2020-11-10T18:45:38-07:00 2020-06-30 990 2019-07-01 030485196 MYELIN REPAIR FOUNDATION INC MYEL 20111 Edinburgh Drive Saratoga CA 95070 Scott Johnson Chief Executive Officer 4088885542 2020-11-10 73.93.41.101 2019 2021-01-29 14:40:06Z Scott Johnson 20111 Edinburgh Dr Saratoga CA 95070 266648 0 X myelinrepair.org X 2002 CA Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by MS 5 4 1 4 0 0 287392 253579 0 0 7293 11669 0 1400 294685 266648 338524 322993 0 0 157202 156307 0 0 6987 42674 75453 538400 554753 -243715 -288105 1552624 1357117 468441 561039 1084183 796078 Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by Multiple Sclerosis. The MRF is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials 0 0 533393 322993 0 We only have one area of program services and that is scientific research to benefit Multiple Sclerosis (MS) patients. Currently our research is focused on experiments to identify biomarkers to indicate repair of myelin damaged by MS. Over the last year, we focused our research on extracellular vesicles(EVs) isolated from blood. We initiated six investigations in North America. We have encouraging preliminary data showing that we can clearly distinguish MS patient EV's from healthy controls and may be able to identify sub-types of MS. 0 0 0 533393 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 5 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 X 5 4 0 0 0 0 0 0 0 1 1 1 0 1 1 1 1 1 1 1 0 0 CA X Louise Savoie 4088885542 2198 Hillstone Dr San Jose CA 95138 Scott Johnson CEO 20.00 X X 120000 0 0 Casey Mcglynn Director 1 0 X 0 0 0 Andy Cates Director 1.0 0 X 0 0 0 Bobby Mehta Director 1.0 0 X 0 0 0 Jim Gidwitz Director 1.0 0 X 0 0 0 120000 0 0 1 0 0 0 0 0 0 0 0 0 253579 0 253579 0 11669 11669 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1400 1400 0 0 1400 266648 13069 0 0 X 272993 272993 0 0 50000 50000 0 120000 120000 26693 17350 4805 4538 9614 6250 1730 1634 6975 6975 60372 60372 4793 3115 863 815 3124 3124 189 189 0 0 554753 533393 14373 6987 18563 123943 909007 846080 622000 387000 3054 94 1552624 1357117 468441 540117 20922 468441 561039 X 1084183 796078 0 0 1084183 796078 1552624 1357117 -288105 0 0 0 0 0 X 0 0 0 X 216766 50000 1007500 287392 253579 1815237 216766 50000 1007500 287392 253579 1815237 1081153 734084 6926 11669 18595 70054 70054 1903886 0 0.38557 0.33404 X Schedule A, Part II, Line 10 Return of prior year's unused grant RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 North America (including Canada and Mexico, but not the United States) 0 0 50000 0 0 50000 North America (including Canada and Mexico, but not the United States) Look for an EV based molecular signature for remyelination using an in vitro model of adult human oligodendrocytes and neurons 50000 cash progress payments 0 contractual amount 1 0 0 0 0 0 0 0 Schedule F, Part I, Line 2 Grants outside the United States are treated the same as grants within the United States with regular required reports and conversations with recipients 1 Cornell University 102 Prospect Street Ithaca NY 14850 150532082 23993 0 contractual amount Use MRI with gradient echo to detect iron in the rim of slowly expanding MS lesions Cornell University 102 Prospect Street Ithaca NY 14850 150532082 74000 0 contractual amount Conduct a longitudinal study of brain endothelial and microglial cell EVs as biomarkers in MS John Hopkins School of Medicine 12529 Collections Center Drive Chicago IL 60693 520595110 125000 0 contractual amount Utilize circulating neuronally derived Evs to identify markers of neurodegeneration and repair Yale University Office of Sponsored Projects 150 Munson Street 25 Science Park New Haven CT 06511 900230377 50000 0 contractual amount Use plasma from MS patients to assess atrocyte exosomal miRNA that correlates with disease progression 3 0 Schedule I, Part I, Line 2 The Universities are subject to terms and conditions of the sponsored research agreement between Universities and the MRF. The researchers' work are reviewed by the MRF committee and by the MRF president. Form 990, Part VI, Section A, Line 9 These are the home address's for the board members: 1.Andy Cates 429 N. Main Street, Suite 100, Memphis, TN 38103 2.Jim Gidwitz 440 S. LaSalle, Suite 3100, Chicago, IL 60605-5020 3.Casey McGlynn 650 Page Mill Road, Palo Alto, CA 94304-1001 4.Bobby Mehta 159 E. Walton Street, Chicago, IL 60611 Form 990, Part VI, Section B, Line 11b Form 990 is reviewed by the CEO and once the CEO approves, it is then forwarded to the board members for their review prior to filing. Board members are encouraged to review and to forward their questions, if any, to the CEO. Form 990, Part VI, Section B, Line 12c Officers, directors and key employees are covered. Any and all conflicts are reviewed by disinterested board members and, if needed, by legal counsel. Persons with a conflict of interest will be restricted from making key decisions for MRF as they relate to the interest unless otherwise approved by the majority of the disinterested board of directors. Form 990, Part VI, Section B, Line 15 Compensation is determined by the board of directors Form 990, Part VI, Section C, Line 19 Financial Statements, governing documents and policies are available upon request for the same period of time set forth in Sec. 6104(D) Form 990, Part IX, Line 11g General Consulting